ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 220 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2021. The put-call ratio across all filers is 1.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $220,870 | -12.7% | 4,788 | -21.8% | 0.01% | +55.6% |
| Q3 2022 | $253,000 | +9.1% | 6,119 | +121.8% | 0.01% | +50.0% |
| Q4 2021 | $232,000 | -37.1% | 2,759 | -28.7% | 0.01% | -45.5% |
| Q2 2021 | $369,000 | +63.3% | 3,869 | +94.9% | 0.01% | +83.3% |
| Q1 2021 | $226,000 | +247.7% | 1,985 | +150.0% | 0.01% | +100.0% |
| Q3 2020 | $65,000 | -90.0% | 794 | -90.5% | 0.00% | -91.7% |
| Q2 2020 | $651,000 | +425.0% | 8,322 | +197.2% | 0.04% | +350.0% |
| Q1 2020 | $124,000 | +1277.8% | 2,800 | +2070.5% | 0.01% | +700.0% |
| Q1 2019 | $9,000 | -98.2% | 129 | -98.4% | 0.00% | -97.9% |
| Q2 2017 | $497,000 | +163.0% | 8,000 | +167.3% | 0.05% | +80.8% |
| Q1 2016 | $189,000 | – | 2,993 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |